VB Devices Closes 1 million Round to Accelerate Commercial Expansion

VB Devices is once again raising capital to expand its commercial activity. The Spanish company that develops, manufactures and markets innovative devices for vascular medicine has closed a $1.08 million (€1 million) financing round through the crowdfunding platform Capital Cell, as confirmed by Federico Grego, CEO and co-founder of VB Devices.

Sixty percent of the investment has been contributed by the current partners of VB Devices, led by Grego and Enric Roche, founder and medical director. The remaining 40% came from new investors, including doctors and vascular surgeons, according to the company’s CEO.

The objective of the round is to accelerate the company’s commercial expansion, with launches in the United Kingdom, Japan, and Latin America during the second quarter of 2022, according to Grego. In addition, VB Devices will expand the range of Varixio, its lead product that is indicated for the treatment of varicose veins, and scale industrial capabilities to gain manufacturing efficiencies.

Read more on the subject and find the latest business news in the world with the born2Invest mobile app.

VB Devices will expand the Varixio range and scale industrial capabilities to gain manufacturing efficiencies

Varixio automates the preparation of sclerosing foam for the treatment of varicose veins through sclerotherapy, standardizing the procedure, adding efficacy, safety and convenience. The product makes it possible to further expand the applicability of this minimally invasive technique, making surgical intervention for the elimination of varicose veins unnecessary in the vast majority of cases.

Varixio began direct marketing in Europe through the ecommerce channel in January 2021, while VB Devices is negotiating commercial collaboration agreements in numerous countries. It currently has distribution contracts in more than twenty countries. The product has the potential to become the reference product for the treatment of varicose veins, a pathology that affects more than 25% of the population and more than 50% of women over the age of fifty.

The prevalence of this pathology manifests itself in more than ten million procedures per year worldwide, and a market that exceeds $1.1 billion and is growing at an annual rate of 6%.

Another product that began commercialization in 2021 was Crabclamp, a solution to ensure that guidewires and catheters remain in place during endovascular procedures. This device avoids the risk of accidental loss of guidewires and contributes to the orderly maintenance of the surgical field, greatly facilitating procedures in situations where the surgeon does not have several assistants available.

Crabclamp has been on sale since January 2021, having already closed more than ten distribution agreements in France, Spain, Portugal, Germany, Austria, Switzerland, Italy, Japan and Nordic countries.

The company closed 2021 with sales of $339,000 (€315,000), the target for 2022 is to achieve $977,000 (€909,000), and for 2023 to exceed $1.6 million (€1.5 million) and reach a positive gross operating profit (Ebitda). In 2021, the company closed its first round of financing also through Capital Cell and raised $1.18 million (€1.1 million).

__

(Featured image by CDC via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.